Navigation Links
Masimo Files Patent Infringement Suit Against Philips
Date:2/3/2009

tening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET(R) Pulse CO-OximetryTM, a breakthrough noninvasive blood constituent monitoring platform that can measure many blood constituents that previously required invasive procedures. Masimo Rainbow SET continuously and noninvasively measures total hemoglobin (SpHbTM), oxygen content (SpOCTM), carboxyhemoglobin (SpCO(R)), methemoglobin (SpMet(R)), and PVITM, in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early detection and treatment of potentially life-threatening conditions. Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at www.masimo.com.

Forward Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors. Important factors that may cause such a difference for Masimo in connection with our litigation with Philips include, but are not limited to: our ability to prevail in the lawsuit against Philips,
'/>"/>

SOURCE Masimo
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Clinicians at Dartmouth-Hitchcock Medical Center Present New Data Showing Masimo Rainbow SET(R) Oximetry and Patient SafetyNet(TM) Improves Patient Outcomes and Reduces the Cost of Care
2. Masimo to Present at Lazard Capital Markets 5th Annual Healthcare Conference
3. Masimo Launches First Non-adhesive Pulse Oximetry Sensor Designed For Extremely Low Birth Weight Babies
4. Masimo Reports Second Quarter 2008 Financial Results
5. Aurora Health Care Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology
6. First Nursing Facility Installation of Masimo Patient SafetyNet(TM) Goes Live With Remarkable Results
7. Dartmouth-Hitchcock Medical Center Evaluation Findings Demonstrate Masimo Patient SafetyNet(TM) Delivers Improvements in Clinical Outcomes and Patient Safety on General Care Floors
8. Masimo Receives FDA Clearance for Noninvasive Total Hemoglobin
9. Saint Barnabas Medical Center Converts to Masimo SET Technology - Establishing a Foundation for the Future of Pulse Oximetry
10. Masimo to Report First Quarter 2008 Financial Results on April 29, 2008
11. Masimo to Report Fourth Quarter and Fiscal Year 2007 Financial Results on February 26, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:NOVAVAX Announces Closing of Public Offering of 6,800,000 Shares of Common Stock 2Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 2Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 3Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 2Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 3Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 4Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 5Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 6Cadence Pharmaceuticals to Webcast October 7th Analyst Day 5086 1Cadence Pharmaceuticals to Webcast October 7th Analyst Day 5086 2Cadence Pharmaceuticals to Webcast October 7th Analyst Day 5086 3Cord Blood America Opens Las Vegas Cryogenic Laboratory 3B Consolidates Offices in Nevada 58510 1Cord Blood America Opens Las Vegas Cryogenic Laboratory 3B Consolidates Offices in Nevada 58510 2Cord Blood America Opens Las Vegas Cryogenic Laboratory 3B Consolidates Offices in Nevada 58510 3US Farms Inc Announces Distribution Partnership With Natures Best 58507 1US Farms Inc Announces Distribution Partnership With Natures Best 58507 2US Farms Inc Announces Distribution Partnership With Natures Best 58507 3